Clinical efficacy of icotinib in patients with advanced nonsquamous non-small cell lung cancer with unknown EGFR mutation status that failed to respond to second-line chemotherapy

Xu, Lu; Xu, Xin-Hua; Yuan, Cheng; Zhang, Jia-Yu; Tang, Xi; Chen, Dian; Wang, Xiao-Long und Zeng, Guang (2018): Clinical efficacy of icotinib in patients with advanced nonsquamous non-small cell lung cancer with unknown EGFR mutation status that failed to respond to second-line chemotherapy. In: Annals of Translational Medicine, Bd. 6, Nr. 20, 405

Abstract

Background: Evaluation of the clinical efficacy and safety of icotinib in advanced nonsquamous non-small cell lung cancer (NSCLC) patients with an unknown EGFR mutation who failed to respond to second-line chemotherapy. Methods: Seventy-six cases of advanced nonsquamous NSCLC were involved in this study from seven hospitals from the Hubei province of China. Patients with an unknown EGFR mutation status were treated with Icotinib, at an oral dosage of 125 mg three times daily. All patients were followed up for at least 1 year to observe the efficacy, adverse reactions, and 1-year survival. Results: The patients' overall objective response rate (ORR) was 34.2%, the disease control rate (DCR) was 75.0%, the clinical benefit rate (CBR) was 80.2%, the median progression-free survival (PFS) was 11.0 months, the median overall survival (OS) was 16.9 months, and the 1-year OS rate was 63.2%. Gender and smoking history were associated with the DCR (P<0.05). Both PFS and OS were significantly higher in groups that had pre-accepted cycles of chemotherapy than in groups that had pre-accepted >6 cycles. Conclusions: Our results demonstrated that icotinib had a better DCR or clinical benefits for treating the patients with unknown EGFR mutation who Failed to respond to second-line chemotherapy in advanced nonsquamous NSCLC, and the adverse effects are tolerable.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 2305-5839
• Sprache: Englisch